NCT05360238 - Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions

Follicular B-cell Non-Hodgkin's LymphomaMantle Cell Lymphoma RecurrentMantle Cell Lymphoma RefractorySmall Lymphocytic Lymphoma, RelapsedWaldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia RefractoryChronic Lymphoid Leukemia in RelapseB-cell Lymphoma Refractory

Interventions

BIOLOGICAL

MB-106

T-cells derived from autologous leukapheresis that are genetically modified.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

14642

University of Rochester Medical Center, Rochester

44195

Cleveland Clinic, Cleveland

98109

Fred Hutchinson Cancer Research Center, Seattle

92868-3201

UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange

02114

Massachusetts General Hospital (MGH), Boston